Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced the appointment of Mary Sheahan as a member of the
Supervisory Board, to be confirmed at the Company’s next General
Meeting of Shareholders. Ms. Sheahan will serve as a member ad
interim of the Company’s Supervisory Board starting December 1,
2022. It is also planned that Ms. Sheahan will assume the role of
Chair of the Audit Committee.
Ms. Sheahan brings over 20 years of experience in private and
publicly listed international pharmaceutical and life science
companies, including as an executive at Avillion, Perrigo, and Elan
Corporation, as well as a non-executive director at Venn Life
Sciences. Throughout her career, she has held significant financial
and other management roles and supported value creation across a
wide range of areas, including supporting development, approval,
and launch of blockbuster products for neurology and immunology
indications. Ms. Sheahan currently serves as CFO of Avillion LLP, a
private equity-backed life sciences company focused on the
co-development and financing of pharmaceutical products. In this
role, she is also responsible for supporting Avillion’s
partnerships with multinational pharmaceutical companies. Mary is
also a qualified chartered accountant and has worked as an auditor
with KPMG.
“I am excited by the opportunity to join CENTOGENE,” said Ms.
Sheahan. “This is a unique time to join the Company, as it has
built the highly diverse CENTOGENE Biodatabank which generates
great value in accelerating data-driven, life-changing answers for
patients around the world. I believe that there is tremendous
opportunity to create substantial value in diagnostics and to
significantly expand our position as the essential life science
partner of choice for pharma in rare and neurodegenerative
diseases.”
“We are very pleased to welcome Ms. Sheahan as a new member of
the Supervisory Board,” stated Peer Schatz, Chairman of the
Supervisory Board of CENTOGENE. “Mary has been instrumental in
financial management, driving strategic decision-making and
delivering value creation for patients and stakeholders over the
past 20 years. We look forward to benefitting from her experiences
in steering public companies, as CENTOGENE is positioned for
significant growth and value creation.”
At the same time, the Company announced that Berndt Modig has
announced his intent to transition off the Supervisory Board. Mr.
Modig, who joined the Company’s Supervisory Board in 2018, intends
to continue to serve on the Board up to the next General Meeting of
Shareholders.
“On behalf of the Supervisory Board and all employees, I would
like to thank Berndt for his great contributions during his time at
CENTOGENE,” added Peer Schatz. “Berndt’s expertise and supervision
has been instrumental in growing CENTOGENE into the Company it is
today and provided guidance and oversight during a time of rapid
change, including the company’s IPO in 2019. We are looking forward
to working with him through the transition and wish him all the
best for the future.”
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodatabank Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 31, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contact:
CENTOGENE
Lennart Streibel
Investor Relations
IR@centogene.com
Ben Legg
Corporate Communications
Press@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024